Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.54 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6653860 | 0.99 | FOLH1 (0.60) | FOLH1HTTTGM2DPP8DPP7 | |
| SCHEMBL7064119 | 0.99 | FOLH1 (0.60) | FOLH1HTTTGM2DPP8DPP7 | |
| SCHEMBL6652290 | 0.96 | HTT (0.63) | FOLH1HTTTGM2LMNASMN1; SMN2 | |
| SCHEMBL6649610 | 0.96 | HTT (0.63) | FOLH1HTTTGM2LMNASMN1; SMN2 | |
| SCHEMBL6650374 | 0.91 | HTT (0.58) | FOLH1HTTLMNASMN1; SMN2 | |
| SCHEMBL19285611 | 0.91 | HTT (0.58) | FOLH1HTTLMNASMN1; SMN2 | |
| SCHEMBL6650048 | 0.90 | HTT (0.55) | FOLH1HTTTGM2SIRT5LMNA | |
| SCHEMBL20556328 | 0.90 | SYK (0.63) | FOLH1HTTSIRT5 | |
| SCHEMBL20556374 | 0.90 | SYK (0.63) | FOLH1HTTSIRT5 | |
| SCHEMBL1022850 | 0.90 | MAPT (0.66) | FOLH1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797110-B1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO KG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-7446102-B2 | Antibacterial amide macrocycles IV | AICURIS GMBH & CO. KG (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO. KG (DE) | 2008-03-27 | — | — | US | disclosed |
| EP-1117652-B1 | TAN-1057 DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-05-26 | — | — | EP | disclosed |
| US-6617332-B1 | Cyclic amidinourea derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-09-09 | — | — | US | disclosed |
| EP-1117652-A1 | TAN-1057 DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000012484-A1 | TAN-1057 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | NOD2, AAAS, AADAC | FOLH1 3157/4885HTT 1796/4885TGM2 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.